Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ET

Company Participants

Andrew McKibben - Vice President-Investor Relations

Chris Peetz - Chief Executive Officer

Peter Radovich - President & Chief Operating Officer

Joanne Quan - Chief Medical Officer

Eric Bjerkholt - Chief Financial Officer

Conference Call Participants

Lili Nsongo - Leerink Partners

Brian Skorney - Baird

Ed Arce - H.C. Wainwright

Operator

Good afternoon, ladies and gentlemen. Thank you for joining today's Mirum Pharmaceuticals Reports Q4 and Year End 2023 Financial Results and Provides Business Update. My name is Tia and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for question-and-answers at the end. [Operator Instructions]

It is my pleasure to pass the call over to Andrew McKibben, Vice President of Investor Relations and Finance. Please proceed.

Andrew McKibben

Thanks, Tia and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals fourth quarter 2023 conference call. I'm joined today by our CEO, Chris Peetz; our President and Chief Operating Officer, Peter Radovich; our Chief Scientific Officer and Head of Research, Pam Vig; our Chief Medical Officer, Joanne Quan; and Eric Bjerkholt, our Chief Financial Officer.

Earlier today, Mirum issued a news release announcing the company's results for the fourth quarter and full year 2023. Copies of this news release and SEC filings can be found in the Investors section of our website.

Before we begin, I'd like to remind you that during the course of this call, we will be making certain forward-looking statements about Mirum, and our programs based on management's current expectations, including statements regarding current and future business plans, development programs and regulatory expectations, strategies, prospects market opportunities, and financial expectations.

Mirum is under no duty to update these statements, and they are subject to numerous risks and uncertainties, and actual results could differ materially from those results anticipated by these statements. Investors should read the risk factors set forth in Mirum's 10-Q for the quarter ended September 30, 2023 and the subsequent reports filed with the SEC.

With that said, I'd like to turn the call over to Chris. Chris?

Chris Peetz

Thanks, Andrew and good afternoon, everyone. I'm excited to kick off an update on the many achievements for Mirum in 2023, another year of significant growth for us and cover highlights for what lies ahead for the company. Our continued progress in 2023 an opportunity ahead, reflects the dedication of the Mirum team to making a difference in the lives of patients and their families around the world.